Overview

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles

Status:
Recruiting

Trial end date:
2024-03-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety and immunogenicity of GSK Biologicals' HZ/su vaccine when given on a two-dose schedule to adults aged 50 years and above who have had a previous episode of shingles.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Vaccines